Skin Cancer

SKIN CANCER
Name:
Institution:
Course code:
Date:
Study I
Long-term outcomes in patients with BRAF V600–mutant metastatic melanoma who received dabrafenib combined with trametinib
This study sought to find the long terms outcomes of patients with BRAF v600 metastatic melanoma upon administration of either a combination of dabrafenib and trametinib or dabrafenib and placebo. One group was assigned to receive a combination dose of 150 mgs of dabrafenib twice a day and 2 mg of trametinib once a day. The second group received a dose of 2 mgs of trametinib daily.
The patient population was a total of 947 patients and 423 of them were randomly assigned to group I. the results showed that there was a 22% of post progression free survival after 3 years on the on the patients who received a combination of dabrafenib and trametinib. For the group that received trametinib only, there was a 12% post progression survival after 3 years. the conclusion was that survival was achievable on patients with BRAF v600 mutant metastatic melanoma if they receive a combination of trametinib and dabrafenib therapy.
Study II
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
The article reports the efficacy and safety outcomes on patients with BRAF V600 metastatic melanoma who received combination or monotherapy dose of trametinib and dabrafenib. The study is longitudinal and took five years. the study population was spit into three groups. Group I received Dabrafenib dose of 150 mg twice a day. Group II received Dabrafenib dose of 150 mg twice a day plus Trametinib dose of 1 mg once daily, or Dabrafenib does of 150 mg twice a day plus Trametinib dose of 2 mg once daily. Group II received a monotherapy dose of Dabrafenib but could cross over to double doses of dabrafenib and trametinib twice a day post progression.
The study had a patient population of 162 individuals. They were split into three groups of 52 people. the patients were over 18 years and the study were international. The results showed that patients who received D + T 150 had overall survival (OS; 4 years, 30%; 5 years, 28%) and progression-free survival (4 and 5 years, both 13%. They also appeared to stabilize with extended follow-up. The results countered the notion that targeted therapies for treating melanoma led to initial rapid response followed by rapid deterioration due to secondary tumor resistance. The analysis shows that there is long term benefit and durable treatment in some patients.
Study IIIFive-year outcomes with dabrafenib plus trametinib in metastatic melanoma.
This study sought to find out the five-year outcomes of dabrafenib and trametinib therapies on metastatic melanoma. The researchers split the study population into two groups. The two groups received a dose of dabrafenib 150 mg twice daily and trametinib 2 mg once daily but were enrolled at different times with different di...